Thomas J. Mcgahren Email and Phone Number
Thomas J. Mcgahren work email
- Valid
- Valid
Thomas J. Mcgahren personal email
- Valid
Thomas J. Mcgahren phone numbers
Experienced biotechnology investment banker, analyst, advisor, entrepreneur and investor. Currently, Managing Director, investment banking, at Griffin Securities, an entrepreneurial boutique investment bank in Manhattan advising startup, private and public biotech companies seeking financing, M&A, and strategic advisory solutions. Particularly of interest are companies with "change the world" aspirations. I leverage my significant experience as a senior biotech analyst at Merrill Lynch covering large, mid and small cap companies (ranked #1 Forbes Drugs Analyst 2008), medical and legal (MD,JD) training and experience representing pharma, biotech and med-tech companies as an attorney at a large international law firm to provide unique and comprehensive medical / scientific / legal / IP / FDA / investment / financial analysis. My experience and interests provide an edge in assessing potential investable propositions and high value-add in my interactions and work with life science companies, sell & buy side, venture capital and private equity firms. A member of the founding group and served on the SAB of Agilis Biotherapeutics (gene therapy for rare genetic CNS diseases (AADC deficiency - EMA approved, BLA pending) which was acquired by PTC Therapeutics (PTCT) in 2018. Member of the founding group of Xylocor (private, phase 2 development)(gene therapy to promote angiogenesis to reduce ischemic burden) currently in phase 2 development. Member of the founding group of MAAVRX (private, preclinical), gene therapy for severe Parkinson's disease. Specialties: investment bankingstrategic advisoryventure capitalbiotechnology synthetic biologygene therapycell therapyrare diseasesbiopharmaceuticals equity researchcompany analysisFDA practice and procedurelegal intellectual propertylicensing financingstart-ups
-
Managing Director, Investment BankingGriffin Securities, Inc. 2010 - PresentNew York, Ny, UsLife sciences investment banker advising private and public biotech, pharma, spec pharma, medtech and diagnostic companies in financing, M&A and strategic matters. Leveraging diverse skill sets, unique educational background (MD, JD), bulge bracket biotech sell-side analyst experience, legal experience representing life science companies at large international law firm, extensive life science industry, venture capital and Wall Street investment community network to provide strategic analysis and advice particularly for companies with cutting-edge science and "change the world" ambitions. Expert at discerning what constitutes biotech "investible propositions," seeking investment, M&A and collaborative opportunities. Particular interest in companies utilizing synthetic biology, cell and gene therapy, to address unmet medical needs. Experience incubating companies, including the company that because Avexis (AVXS) (acquired by Novartis), provided basis for launching Agilis Biotherapeutics (www.agilisbio.com), focused on gene therapy for rare CNS diseases. (Member of founding group and Scientific Advisory Board of Agilis). Significant work for companies active in synthetic biology such as (XON) and its collaborating companies. Also asked to consult for Celgene on its acquisitions prior to joining Griffin.
-
Member Of Founding Group, Member Of Scientific Advisory Board (Sab)Agilis Biotherapeutics Dec 2013 - Aug 2018Member of founding group and Scientific Advisory Board (SAB) of Agilis Biotherapeutics, www.agilisbio.com, a biotechnology company focused on designing and engineering first-in-class gene therapy to address rare CNS diseases. (Acquired by PTC Therapeutics (PTCT) Aug. 2018). Lead candidate, AGIL-AADC is pre-BLA for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. The company received a Rare Pediatric Disease designation, which would entitle it to a Priority Review Voucher upon approval of AGIL-AADC. Pipeline candidates include AGIL-FA for Friedreich ataxia (partnered with Intrexon (NYSE: XON)) and AGIL-AS for Angelman Syndrome. Agilis is currently conducting a Series C financing. The launch of Agilis was based on extensive analysis of potential rare disease indications, therapeutic options and licensing possibilities. Actively participated in sourcing and securing the science, management, financing, licensing, collaborations, trademark/logo etc.
-
Scientific AdvisorChenango Capital 2010 - 2013Greensboro, Nc, UsAssisted with assessment and due diligence of potential life sciences investment opportunities for early state VC fund formed by alumni of Colgate University. Leveraged medical, legal and Wall Street biotech analyst background. -
Senior Biotechnology AnalystMerrill Lynch Apr 2002 - 2009New York, Ny, UsSenior Director, Senior Biotechnology Analyst. Forbes #1 Drugs Analyst ranking 2008. Responsible for all aspects of sell-side research: due diligence, launching coverage, financial modeling, industry analysis, surveys, Merrill Lynch health conferences, marketing, roadshows, medical conferences, court hearings, deal vetting, collaboration with capital markets and derivative teams. Leveraged particular expertise in medical, legal, IP, FDA, and regulatory issues. Routinely consulted by other Merrill health science equity research teams, particularly on IP and legal matters. Covered or supervised coverage of large, mid and small cap biotechnology companies including CELG, GENZ, AMGN, BIIB, BMRN, AMLN, OSIP, OREX, ARNA, ALTU, PDLI, MLNM, KERX, ALTH, AFFY, ONXX, COLY, RIGL. Representative speaking engagements: "Valuation of Patent Protected Biotech Products," ACI (American Conf. Institute 2006; "Building IP Asset Management Competency," Northwestern Kellogg Biotech Conf 2005 -
Biotechnology AnalystBanc Of America Securities Apr 2001 - Apr 2002Charlotte, Nc, UsAssociate biotechnology analyst on II-ranked team covering large, mid and small cap companies. Drafted initiations, event and earnings notes. Routinely consulted by other BofA analysts, particularly on IP, FDA, medical issues in view of expertise and experience as a physician and attorney representing biotech and big pharma companies as a litigator. -
Attorney, LitigatorKaye Scholer Llp Sep 1992 - Mar 2001Litigator representing pharmaceutical, biotechnology and med-tech companies in intellectual property, FDA and corporate matters at major international law firm. Developed expertise in biopharma industry, FDA practice & procedure and particularly biotech intellectual property litigation. Participated in all phases of litigation, counseling and business development. Conducted due diligence regarding IP aspects of corporate transactions. Representative clients included, e.g., Pfizer, Chiron, Bristol Myers, Johnson&Johnson. Recruited from law firm by Banc of America Securities to join top-ranked biotech equity research team.
Thomas J. Mcgahren Skills
Thomas J. Mcgahren Education Details
-
The University Of Texas School Of LawJd -
University Of Virginia School Of MedicineMd
-
Colgate UniversityPolitical Science
Frequently Asked Questions about Thomas J. Mcgahren
What company does Thomas J. Mcgahren work for?
Thomas J. Mcgahren works for Griffin Securities, Inc.
What is Thomas J. Mcgahren's role at the current company?
Thomas J. Mcgahren's current role is Managing Director, Griffin Securities, Inc..
What is Thomas J. Mcgahren's email address?
Thomas J. Mcgahren's email address is tm****@****msn.com
What is Thomas J. Mcgahren's direct phone number?
Thomas J. Mcgahren's direct phone number is +164644*****
What schools did Thomas J. Mcgahren attend?
Thomas J. Mcgahren attended The University Of Texas School Of Law, University Of Virginia School Of Medicine, Colgate University.
What skills is Thomas J. Mcgahren known for?
Thomas J. Mcgahren has skills like Venture Capital, Mergers And Acquisitions, Biotechnology, Valuation, Lifesciences, Financial Modeling, Investment Banking, Biopharmaceuticals, Intellectual Property, Due Diligence, Strategy, Pharmaceutical Industry.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial